Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

NCT06056921 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

SLE (Systemic Lupus)
Sjogren's Syndrome
Systemic Scleroderma
Dermatomyositis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions

BIOLOGICAL: CD19 targeted CAR-T cells

Sponsor

Chongqing Precision Biotech Co., Ltd